Infectious Diseases Research

Below are current clinical trials.

223 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Assess the Burden of Respiratory Syncytial Virus Infections in Older Adults in a North American Community

   Rochester, Minn.

   The primary purpose of this study is to estimate the incidence rate of confirmed respiratory syncytial virus (RSV) (and other confirmed respiratory viruses) infections and associated adverse outcomes.

2. A Study to Collect Tissue, Fluids, Blood and/or Fungal Samples in Patients with Pulmonary and Extrapulmonary Coccidioidomycosis

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a biorepository of tissue, fluid and fungal specimens for future studies.

3. A Study To Evaluate MesilatE For Treating Hospitalized Patients With COVID-19 (Enrolling By Invitation Only)

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary purpose of this study is to determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

    

    

4. PC945 Prophylaxis Or Pre-emptive Therapy Against Pulmonary Aspergillosis In Lung Transplant Recipients

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and tolerability of PC945 for the prevention of fungal aspergillus infections in the lung in patients who have received a lung transplant.

5. Efficacy And Safety Of COVID-19 Vaccine In Cancer Patients

   Jacksonville, Fla.

   We hypothesize that cancer patients on cytotoxic chemotherapy which affect immune response may not mount adequate immune response to COVID-19 vaccines.

   Aims, purpose, or objectives:

   1. To determine the antibody response to COVID-19 vaccine after vaccination.
   2. To assess the adverse events of COVID-19 vaccines in cancer patients.
   3. To determine the incidence and severity of COVID-19 infection after the vaccination.

6. SER-109 Versus Placebo To Prevent Recurrent Clostridium Difficile Infection (RCDI)

   Rochester, Minn.

   The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.

7. HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

   Rochester, Minn.

   This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN study (NCT01263587).

8. Fresh Versus Frozen Stool for Fecal Transplant in Children

   Rochester, Minn.

   The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent Clostridium difficile infections in children. In the current protocols, which are more than 90% effective, each child who is receiving a fecal transplant has to provide their own donor stool, usually from a parent or close relative. This requires considerable screening costs for each case and is logistically complicated as the donor must be present and must stool just prior to the transplant. The investigators hope to show that a small number of healthy donors can provide stool samples which can be frozen and banked and then thawed for use in numerous patients. The primary goal is to show that Clostridium difficile will be eradicated as effectively (Greater than 90% success) when using the stool from the frozen donors.

   The study will also evaluate the inflammatory response and intestinal microbiome in young children aged 1-3 years with Clostridium difficile infections to better predict which ones will respond to fecal transplantation and which ones have incidental infections. For this question the investigators will gather stool samples to check for lactoferrin, calprotectin, and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal transplants. The goal is to see if there is an intestinal microbiome that predisposes some children to getting sick from Clostridium difficile versus just having it incidentally.

9. A Study Of Glecaprevir (GLE)/Pibrentasvir (PIB) In Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 Or 6 Infection And Compensated Cirrhosis

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.

10. A Study To Assess Monoclonal B-cell Lymphocytosis In Individuals With Chronic Hepatitis C

    Rochester, Minn.

    The purpose of this study is to:

    1. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with DAA, and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic

    2. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the HCV genotype

    3. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA